BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes Obes Metab 2020;22 Suppl 1:16-31. [PMID: 32267077 DOI: 10.1111/dom.13969] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. Pharmacol Res 2021;172:105859. [PMID: 34461222 DOI: 10.1016/j.phrs.2021.105859] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pirklbauer M, Bernd M, Fuchs L, Staudinger P, Corazza U, Leierer J, Mayer G, Schramek H. Empagliflozin Inhibits Basal and IL-1β-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells. Int J Mol Sci 2020;21:E8189. [PMID: 33139635 DOI: 10.3390/ijms21218189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yaribeygi H, Maleki M, Atkin SL, Jamialahmadi T, Sahebkar A. Impact of Incretin-Based Therapies on Adipokines and Adiponectin. J Diabetes Res 2021;2021:3331865. [PMID: 34660808 DOI: 10.1155/2021/3331865] [Reference Citation Analysis]
4 Wang Y, Liu T, Ma F, Lu X, Mao H, Zhou W, Yang L, Li P, Zhan Y. A Network Pharmacology-Based Strategy for Unveiling the Mechanisms of Tripterygium Wilfordii Hook F against Diabetic Kidney Disease. J Diabetes Res 2020;2020:2421631. [PMID: 33274236 DOI: 10.1155/2020/2421631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zhou W, Zhou X, Zhang Y, Wang Y, Wu W, Zhang H, Zhao T, Peng L, Zhao H, Li P, Okamoto H. A Network Pharmacology-Based Approach for Exploring Key Active Compounds and Pharmacological Mechanisms of Tangshen Formula for Treatment of Diabetic Nephropathy. Journal of Diabetes Research 2021;2021:1-17. [DOI: 10.1155/2021/8833688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Palacios-ramirez R, Lima-posada I, Bonnard B, Genty M, Fernandez-celis A, Hartleib-geschwindner J, Foufelle F, Lopez-andres N, Bamberg K, Jaisser F. Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice. Front Physiol 2022;13:859812. [DOI: 10.3389/fphys.2022.859812] [Reference Citation Analysis]
7 Xie D, Li K, Ma T, Jiang H, Wang F, Huang M, Sheng Z, Xie Y. Therapeutic Effect and Safety of Tripterygium Glycosides Combined With Western Medicine on Type 2 Diabetic Kidney Disease: A Meta-Analysis. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2021.12.006] [Reference Citation Analysis]
8 Huang Z, Zhang H, Luo Y, Wei C, Zhao Y, Huang Y, Zhang L, Chen W, He L, Liu H, Sun L, Liu F, Xiao L. The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis. Ren Fail 2021;43:781-95. [PMID: 33941037 DOI: 10.1080/0886022X.2021.1919528] [Reference Citation Analysis]
9 Wen Y, Liu Y, Huang Q, Liu R, Liu J, Zhang F, Liu S, Jiang Y. Moringa oleifera Lam. seed extract protects kidney function in rats with diabetic nephropathy by increasing GSK-3β activity and activating the Nrf2/HO-1 pathway. Phytomedicine 2021;95:153856. [PMID: 34856477 DOI: 10.1016/j.phymed.2021.153856] [Reference Citation Analysis]
10 Wang L, Wang Z, Yang Z, Yang K, Yang H. Study of the Active Components and Molecular Mechanism of Tripterygium wilfordii in the Treatment of Diabetic Nephropathy. Front Mol Biosci 2021;8:664416. [PMID: 34164430 DOI: 10.3389/fmolb.2021.664416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Ther 2021;12:1791-7. [PMID: 34050896 DOI: 10.1007/s13300-021-01085-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Inacio MD, Costa MC, Lima TFO, Figueiredo ID, Motta BP, Spolidorio LC, Assis RP, Brunetti IL, Baviera AM. Pentoxifylline mitigates renal glycoxidative stress in obese mice by inhibiting AGE/RAGE signaling and increasing glyoxalase levels. Life Sci 2020;258:118196. [PMID: 32763295 DOI: 10.1016/j.lfs.2020.118196] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ding H, Zhang L, Yang Q, Zhang X, Li X. Epigenetics in kidney diseases. Adv Clin Chem 2021;104:233-97. [PMID: 34462056 DOI: 10.1016/bs.acc.2020.09.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lepoittevin M, Giraud S, Kerforne T, Barrou B, Badet L, Bucur P, Salamé E, Goumard C, Savier E, Branchereau J, Battistella P, Mercier O, Mussot S, Hauet T, Thuillier R. Preservation of Organs to Be Transplanted: An Essential Step in the Transplant Process. IJMS 2022;23:4989. [DOI: 10.3390/ijms23094989] [Reference Citation Analysis]
15 Danta CC, Boa AN, Bhandari S, Sathyapalan T, Xu SZ. Recent advances in drug discovery for diabetic kidney disease. Expert Opin Drug Discov 2021;16:447-61. [PMID: 33003971 DOI: 10.1080/17460441.2021.1832077] [Reference Citation Analysis]
16 Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, Carriazo S, Sanchez-Niño MD, Ramos AM, Ruiz-Ortega M, Ortiz A, Sanz AB. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Int J Mol Sci 2020;21:E4113. [PMID: 32526941 DOI: 10.3390/ijms21114113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
17 Danta CC. Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection. ACS Pharmacol Transl Sci 2020;3:1020-2. [PMID: 33062955 DOI: 10.1021/acsptsci.0c00097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Quan KY, Yap CG, Jahan NK, Pillai N. Review of early circulating biomolecules associated with diabetes nephropathy - Ideal candidates for early biomarker array test for DN. Diabetes Res Clin Pract 2021;182:109122. [PMID: 34742785 DOI: 10.1016/j.diabres.2021.109122] [Reference Citation Analysis]
19 Song A, Jiang A, Xiong W, Zhang C. The Role of CXCL12 in Kidney Diseases: A Friend or Foe? Kidney Dis (Basel) 2021;7:176-85. [PMID: 34179113 DOI: 10.1159/000514913] [Reference Citation Analysis]
20 López-Andrés N, Jaisser F, Barrera-Chimal J. Editorial: Kidney and Distant Organ Crosstalk in Health and Disease. Front Physiol 2021;12:712535. [PMID: 34276426 DOI: 10.3389/fphys.2021.712535] [Reference Citation Analysis]
21 Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. The Impact of Incretin-Based Medications on Lipid Metabolism. J Diabetes Res 2021;2021:1815178. [PMID: 35005028 DOI: 10.1155/2021/1815178] [Reference Citation Analysis]
22 Li W, Sun J, Zhou X, Lu Y, Cui W, Miao L. Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy. Front Pharmacol 2021;12:780790. [PMID: 34867412 DOI: 10.3389/fphar.2021.780790] [Reference Citation Analysis]
23 Yang X, Feng J, Liang W, Zhu Z, Chen Z, Hu J, Yang D, Ding G. Roles of SIRT6 in kidney disease: a novel therapeutic target. Cell Mol Life Sci 2021. [PMID: 34950960 DOI: 10.1007/s00018-021-04061-9] [Reference Citation Analysis]
24 Jin, Zhang Y, Zhang Y, Duan L, Zhou R, Duan Y, Sun Y, Lian F, Tong X. Panax Ginseng C.A.Mey. as Medicine: The Potential Use of Panax Ginseng C.A.Mey. as a Remedy for Kidney Protection from a Pharmacological Perspective. Front Pharmacol 2021;12:734151. [PMID: 34512359 DOI: 10.3389/fphar.2021.734151] [Reference Citation Analysis]
25 Liew ZH, Tan PH, Foo M, Kee T, Ho QY. Nodular glomerulosclerosis in a kidney transplant recipient with impaired glucose tolerance: diabetic or idiopathic? A case report and literature review. CEN Case Rep 2021;10:273-80. [PMID: 33393072 DOI: 10.1007/s13730-020-00546-x] [Reference Citation Analysis]